Neoclarityn

RSS

desloratadine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Neoclarityn. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Neoclarityn.

This EPAR was last updated on 22/06/2018

Authorisation details

Product details
Name
Neoclarityn
Agency product number
EMEA/H/C/000314
Active substance
desloratadine
International non-proprietary name (INN) or common name
desloratadine
Therapeutic area (MeSH)
  • Rhinitis, Allergic, Perennial
  • Urticaria
  • Rhinitis, Allergic, Seasonal
Anatomical therapeutic chemical (ATC) code
R06AX27
Publication details
Marketing-authorisation holder
Merck Sharp & Dohme B.V. 
Revision
37
Date of issue of marketing authorisation valid throughout the European Union
15/01/2001
Contact address

Waarderweg 39
2031 BN Haarlem
The Netherlands

Product information

15/06/2018 Neoclarityn - EMEA/H/C/000314 - T/0088

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antihistamines for systemic use

Therapeutic indication

Neoclarityn is indicated for the relief of symptoms associated with:

  • allergic rhinitis
  • urticaria

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
Average
1 rating